Hepatic Encephalopathy in Patients with Cirrhosis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Sherlock's Diseases of the Liver and Biliary System

• Publication date

  2011-05-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/9781119237662.CH10
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Letter: stepwise diagnosis in covert hepatic encephalopathy – critical flicker frequency and MELD‐score as a first‐step approach. Replication and pitfalls

  2017cited by this paper
• Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

  2017cited by this paper
• Branched-chain amino acids for people with hepatic encephalopathy.

  2017cited by this paper
• A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis

  2017cited by this paper
• Probiotics for people with hepatic encephalopathy.

  2017cited by this paper
• Functional cortical connectivity is disturbed in patients with cirrhosis even when neuropsychometric performance is unimpaired

  2017cited by this paper
• Probiotics are helpful in hepatic encephalopathy: a meta‐analysis of randomized trials

  2016cited by this paper
• Techniques for Transjugular Intrahepatic Portosystemic Shunt Reduction and Occlusion.

  2016cited by this paper
• Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta‐analysis

  2016cited by this paper
• Hepatic Encephalopathy: Pharmacological Therapies Targeting Ammonia

  2016cited by this paper
• A low‐cost, user‐friendly electroencephalographic recording system for the assessment of hepatic encephalopathy

  2016cited by this paper
• Liver transplantation significantly improves global functioning and cerebral processing

  2016cited by this paper
• Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study

  2016cited by this paper
• Hepatic encephalopathy expands the predictivity of model for end‐stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts

  2016cited by this paper
• Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients

  2016cited by this paper
• New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy.

  2016cited by this paper
• Qualifying and quantifying minimal hepatic encephalopathy

  2016cited by this paper
• Endovascular Management of Refractory Hepatic Encephalopathy Complication of Transjugular Intrahepatic Portosystemic Shunt (TIPS): Comprehensive Review and Clinical Practice Algorithm

  2016cited by this paper
• Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities.

  2016cited by this paper
• Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.

  2015cited by this paper
• Functional brain network changes associated with clinical and biochemical measures of the severity of hepatic encephalopathy

  2015cited by this paper
• Cerebral white matter lesions in patients with cirrhosis – causative for hepatic encephalopathy or bystanders?

  2015cited by this paper
• The role of zinc in liver cirrhosis.

  2015cited by this paper
• Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis.

  2015cited by this paper
• Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation

  2014cited by this paper
• Alterations of the human gut microbiome in liver cirrhosis

  2014cited by this paper
• Pre‐transjugular intrahepatic portosystemic shunts (TIPS) prediction of post‐TIPS overt hepatic encephalopathy: The Critical Flicker Frequency is more accurate than psychometric tests

  2014cited by this paper
• Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

  2014cited by this paper
• Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.

  2014cited by this paper
• Covert hepatic encephalopathy: agreement and predictive validity of different indices.

  2014cited by this paper
• Brain magnetic resonance in hepatic encephalopathy.

  2014cited by this paper
• Cerebral effects of ammonia in liver disease: current hypotheses

  2014cited by this paper
• Challenges in Diagnosing Hepatic Encephalopathy

  2014cited by this paper
• Reestablishing Brain Networks in Patients without Overt Hepatic Encephalopathy after Liver Transplantation

  2014cited by this paper
• Cognitive impairment and electroencephalographic alterations before and after liver transplantation: What is reversible?

  2014cited by this paper
• Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.

  2014cited by this paper
• Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

  2014cited by this paper
• Increased risk of cognitive impairment in cirrhotic patients with bacterial infections.

  2013cited by this paper
• Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy

  2013cited by this paper
• Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial

  2013cited by this paper
• Hepatic encephalopathy: clinical aspects and pathogenetic concept.

  2013cited by this paper
• Sodium benzoate for treatment of hepatic encephalopathy.

  2013cited by this paper
• Synaptic plasticity in hepatic encephalopathy - a molecular perspective.

  2013cited by this paper
• Inflammation and hepatic encephalopathy.

  2013cited by this paper
• Cirrhosis-related Parkinsonism: prevalence, mechanisms and response to treatments.

  2013cited by this paper
• Gene expression profiling in the cerebral cortex of patients with cirrhosis with and without hepatic encephalopathy

  2013cited by this paper
• 190 AST-120 (SPHERICAL CARBON ADSORBENT) IN COVERT HEPATIC ENCEPHALOPATHY: RESULTS OF THE ASTUTE TRIAL

  2013cited by this paper
• A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy

  2013cited by this paper
• The slowed brain: cortical oscillatory activity in hepatic encephalopathy.

  2013cited by this paper
• Brain metabolism in patients with hepatic encephalopathy studied by PET and MR.

  2013cited by this paper
• Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy

  2013cited by this paper
• The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus

  2013cited by this paper
• Simple tools for complex syndromes: a three-level difficulty test for hepatic encephalopathy.

  2012cited by this paper
• Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis

  2012cited by this paper
• Hospital Readmissions Among Patients With Decompensated Cirrhosis

  2012cited by this paper
• A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy

  2012cited by this paper
• Partial pressure of NH₃ in cirrhotic patients with and without hepatic encephalopathy.

  2011cited by this paper
• Minimal Hepatic Encephalopathy Is Associated With Falls

  2011cited by this paper
• Interorgan ammonia metabolism in liver failure: the basis of current and future therapies

  2011cited by this paper
• Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review

  2011cited by this paper
• Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

  2010cited by this paper
• Rifaximin treatment in hepatic encephalopathy.

  2010cited by this paper
• Predictors of the recurrence of hepatic encephalopathy in lactulose‐treated patients

  2010cited by this paper
• A Long-Term Study of Changes in the Volume of Brain Ventricles and White Matter Lesions After Successful Liver Transplantation

  2010cited by this paper
• Neurocognitive-neurological complications of liver transplantation: a review

  2010cited by this paper
• Improving the inhibitory control task to detect minimal hepatic encephalopathy.

  2010cited by this paper
• Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy

  2010cited by this paper
• 152 TRANSDERMAL RIVASTIGMINE FOR TREATMENT OF ENCEPHALOPATHY IN LIVER CIRRHOSIS – A RANDOMIZED PLACEBO CONTROLLED TRIAL (TREC TRIAL)

  2010cited by this paper
• Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy

  2010cited by this paper
• Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature

  2010cited by this paper
• Successful Embolization of a Spontaneous Mesocaval Shunt Using the Amplatzer Vascular Plug II

  2010cited by this paper
• Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence

  2010cited by this paper
• Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy

  2010cited by this paper
• Clinical course of alcoholic liver cirrhosis: A Danish population‐based cohort study

  2010cited by this paper
• Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis

  2010cited by this paper
• Three targets of branched-chain amino acid supplementation in the treatment of liver disease.

  2010cited by this paper
• Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.

  2010cited by this paper
• Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy

  2010cited by this paper
• Emerging drugs for hepatic encephalopathy

  2009cited by this paper
• Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines

  2009cited by this paper
• Relationship Between Changes in Brain MRI and 1H-MRS, Severity of Chronic Liver Damage, and Recovery After Liver Transplantation

  2009cited by this paper
• Night‐time sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis

  2009cited by this paper
• A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.

  2009cited by this paper
• Hepatic encephalopathy and fitness to drive.

  2009cited by this paper
• Are Acquired Hepatocerebral Degeneration and Hepatic Myelopathy Reversible?

  2009cited by this paper
• Neurotransmitter Receptor Imbalances in Motor Cortex and Basal Ganglia in Hepatic Encephalopathy

  2009cited by this paper
• Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation

  2009cited by this paper
• Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines

  2009cited by this paper
• Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines

  2009cited by this paper
• Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation.

  2009cited by this paper
• Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis

  2009cited by this paper
• Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft.

  2009cited by this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cited by this paper
• Severe sepsis in cirrhosis

  2009cited by this paper
• Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation

  2009cited by this paper
• L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats

  2009cited by this paper
• Pathogenetic mechanisms of hepatic encephalopathy

  2008cited by this paper
• L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.

  2008cited by this paper
• Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.

  2008cited by this paper
• Quantitative cerebral water content mapping in hepatic encephalopathy

  2008cited by this paper

• Effect of zinc supplementation on atherogenic risk indices in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial

  2025cites this paper
• Determination of the Relationship Between Urinary Albumin to Creatinine Ratio and the Severity of Liver Disease in Patient with Decompensated Cirrhosis of Liver

  2025cites this paper
• Meta‐analysis of probiotics efficacy in the treatment of minimum hepatic encephalopathy

  2024cites this paper
• Improving Medical Outcomes through At-Home, Longitudinal Health Monitoring

  2024cites this paper
• The association of testosterone with sarcopenia and frailty in chronic liver disease

  2023cites this paper
• Novel Agents in the Management of Hepatic Encephalopathy: A Review

  2021cites this paper
• The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis

  2021cites this paper
• Endoscopic management of acute oesophageal variceal bleeding within 12 hours of admission is superior to 12–24 hours

  2020cites this paper
• "Correlation of Albumin-Bilirubin (ALBI) Score with Child-Turcotte-Pugh (CTP) Score in the Evaluation of Liver Cirrhosis "

  2019cites this paper
• Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy.

  2019cites this paper
• Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post‐therapeutic outcome and prognostic indicators

  2019cites this paper
• Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

  2019cites this paper
• The emergency medicine evaluation and management of the patient with cirrhosis

  2018influential citation
• AGGRAVATING FACTORS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CHRONIC LIVER DISEASE : OUR EXPERIENCE AT TEACHING HOSPITAL IN SOUTHERN PUNJAB , PAKISTAN

  2017cites this paper
• The correlation of serum zinc concentration with liver cirrhosis events

  2017cites this paper
• Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy

  2017cites this paper
• Prognostic assessment of repeatedly measured time-dependent biomarkers, with application to dilated cardiomyopathy

  2017cites this paper
• Effective Factors for Risk of Death in Patients with Cirrhosis Using Competing Risks Model

  2016cites this paper
• A Study of Non Traumatic Coma with Respect to Etiology and Outcome

  2016cites this paper
• FEATURES OF PHARMACOTHERAPY OF HEPATIC ENCEPHALOPATHY MANIFESTATIONS IN LIVER CIRRHOSIS

  2015cites this paper
• The influence of the oxidative stress on the evolution of portosystemic encephalopathy.

  2014cites this paper
• Precipitating Factors and Hospital Outcome of Hepatic Encephalopathy In Cirrhotic Patients at Tertiary Centre in Egypt

  2012cites this paper
• Assessment the Role of L-Carnitine in Improving Hepatic Encephalopathy Using MR Spectroscopy

  2012influential citation